Clinical trials: Alogenic Hematopoietic Transplant

Graft vs Host Disease, Alogenic Hematopoietic Transplant

Rituximab for GVHD

• Withdrawn
• Age: Up to 70 years
• Phase 2

This is a prospective, open-label pilot study in which 4 doses of Rituximab are administered to patients who have developed SR-aGVHD following allogeneic hematopoietic transplant (AHT).

Trial name

Rituximab GVHD (NCT00578591)

Testing

Rituximab

Where

2 sites in United States

Sponsor

Baylor College of Medicine